🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the battle against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating globally, with figures suggesting over 82 million instances per year. Especially elevated rates are observed in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have reached a record high, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune step in the face of rising global incidence, the spread of superbugs and the very limited available drugs currently available.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The WHO has listed it as a "priority pathogen". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the American regulatory agency in December for treating gonorrhoea. This disease can lead to serious health problems, including infertility. Researchers believe that specific application of this new drug will help delay the development of resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in the same week. This treatment, which is employed against urinary tract infections, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.

“This authorization represents a major breakthrough in the management of superbug gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Testing Results and Global Access

As per data released by a prominent scientific publication, the new drug successfully treated the vast majority of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which involves two antibiotics. The trial enrolled nearly 1,000 patients from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its unique model, GARDP has the authority to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors treating patients have shared positive views. Having a easy-to-administer therapy of this kind is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for people and to prevent the spread of untreatable gonorrhoea globally.